CY1109949T1 - Χρηση αναστολεων cox-2 για τη θεραπεια σχιζοφρενειας, διαταραχων παραισθησεων - Google Patents
Χρηση αναστολεων cox-2 για τη θεραπεια σχιζοφρενειας, διαταραχων παραισθησεωνInfo
- Publication number
- CY1109949T1 CY1109949T1 CY20101100270T CY101100270T CY1109949T1 CY 1109949 T1 CY1109949 T1 CY 1109949T1 CY 20101100270 T CY20101100270 T CY 20101100270T CY 101100270 T CY101100270 T CY 101100270T CY 1109949 T1 CY1109949 T1 CY 1109949T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorders
- cox
- treatment
- diagnosis
- inhibitors
- Prior art date
Links
- 229940111134 coxibs Drugs 0.000 title abstract 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 abstract 3
- 201000000980 schizophrenia Diseases 0.000 abstract 3
- 208000004547 Hallucinations Diseases 0.000 abstract 2
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001534 risperidone Drugs 0.000 abstract 1
- 208000016686 tic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129320A DE10129320A1 (de) | 2001-06-19 | 2001-06-19 | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| US36490402P | 2002-03-14 | 2002-03-14 | |
| EP05024864A EP1627639B1 (en) | 2001-06-19 | 2002-05-31 | Use of COX-2 inhibitors for the treatment of affective disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109949T1 true CY1109949T1 (el) | 2014-09-10 |
Family
ID=26009543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100270T CY1109949T1 (el) | 2001-06-19 | 2010-03-22 | Χρηση αναστολεων cox-2 για τη θεραπεια σχιζοφρενειας, διαταραχων παραισθησεων |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040204469A1 (https=) |
| EP (2) | EP1397145B1 (https=) |
| JP (2) | JP4205577B2 (https=) |
| AP (1) | AP1512A (https=) |
| AT (2) | ATE452642T1 (https=) |
| AU (1) | AU2002312967A1 (https=) |
| CA (1) | CA2448025C (https=) |
| CY (1) | CY1109949T1 (https=) |
| DE (2) | DE60234873D1 (https=) |
| DK (2) | DK1397145T3 (https=) |
| EA (1) | EA009780B1 (https=) |
| ES (2) | ES2271269T3 (https=) |
| OA (1) | OA12627A (https=) |
| PT (2) | PT1627639E (https=) |
| SI (1) | SI1627639T1 (https=) |
| WO (1) | WO2002102297A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| WO2004047844A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Pharmaceuticals, Inc. | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| MXPA05012391A (es) * | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamiento de trastornos psicoticos y depresivos. |
| EP1625333A1 (en) | 2003-05-21 | 2006-02-15 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
| CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| EP1687000A2 (en) * | 2003-11-19 | 2006-08-09 | Glaxo Group Limited | Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders |
| EP1687001A2 (en) * | 2003-11-19 | 2006-08-09 | Glaxo Group Limited | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| EP2246086A3 (en) | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
| US20070281927A1 (en) * | 2006-06-06 | 2007-12-06 | Shanthakumar Tyavanagimatt | Anti-inflammatory and analgesic compositions and related methods |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| JP5144104B2 (ja) | 2007-04-09 | 2013-02-13 | ユニ・チャーム株式会社 | 伸縮性複合シート及びそれを用いた使い捨て着用物品 |
| EP2485744A4 (en) * | 2009-10-09 | 2014-01-22 | Prothera Inc | COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED |
| EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| EP2340818A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of venlafaxine and celecoxib |
| AU2018378348B2 (en) | 2017-12-05 | 2024-09-19 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| EP3746138B1 (en) | 2018-02-02 | 2025-12-10 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
| AU1041599A (en) * | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6465458B1 (en) * | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
-
2002
- 2002-05-31 EA EA200301291A patent/EA009780B1/ru not_active IP Right Cessation
- 2002-05-31 DK DK02738138T patent/DK1397145T3/da active
- 2002-05-31 JP JP2003504886A patent/JP4205577B2/ja not_active Expired - Fee Related
- 2002-05-31 US US10/480,600 patent/US20040204469A1/en not_active Abandoned
- 2002-05-31 EP EP02738138A patent/EP1397145B1/en not_active Expired - Lifetime
- 2002-05-31 EP EP05024864A patent/EP1627639B1/en not_active Expired - Lifetime
- 2002-05-31 ES ES02738138T patent/ES2271269T3/es not_active Expired - Lifetime
- 2002-05-31 AU AU2002312967A patent/AU2002312967A1/en not_active Abandoned
- 2002-05-31 AT AT05024864T patent/ATE452642T1/de active
- 2002-05-31 DE DE60234873T patent/DE60234873D1/de not_active Expired - Lifetime
- 2002-05-31 PT PT05024864T patent/PT1627639E/pt unknown
- 2002-05-31 AT AT02738138T patent/ATE338557T1/de active
- 2002-05-31 DK DK05024864.0T patent/DK1627639T3/da active
- 2002-05-31 DE DE60214542T patent/DE60214542T2/de not_active Expired - Lifetime
- 2002-05-31 WO PCT/EP2002/006013 patent/WO2002102297A2/en not_active Ceased
- 2002-05-31 ES ES05024864T patent/ES2336682T3/es not_active Expired - Lifetime
- 2002-05-31 AP APAP/P/2003/002934A patent/AP1512A/en active
- 2002-05-31 CA CA2448025A patent/CA2448025C/en not_active Expired - Fee Related
- 2002-05-31 OA OA1200300328A patent/OA12627A/en unknown
- 2002-05-31 SI SI200230890T patent/SI1627639T1/sl unknown
- 2002-05-31 PT PT02738138T patent/PT1397145E/pt unknown
-
2008
- 2008-07-22 JP JP2008188890A patent/JP4824727B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-22 CY CY20101100270T patent/CY1109949T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE452642T1 (de) | 2010-01-15 |
| DK1627639T3 (da) | 2010-04-26 |
| JP2004534066A (ja) | 2004-11-11 |
| JP4205577B2 (ja) | 2009-01-07 |
| DE60214542D1 (de) | 2006-10-19 |
| EP1627639A2 (en) | 2006-02-22 |
| CA2448025C (en) | 2011-07-05 |
| OA12627A (en) | 2006-06-13 |
| PT1397145E (pt) | 2006-10-31 |
| AU2002312967A1 (en) | 2003-01-02 |
| EA200301291A1 (ru) | 2004-06-24 |
| DE60214542T2 (de) | 2006-12-21 |
| EP1397145B1 (en) | 2006-09-06 |
| CA2448025A1 (en) | 2002-12-27 |
| EP1627639B1 (en) | 2009-12-23 |
| DK1397145T3 (da) | 2007-01-02 |
| AP2003002934A0 (en) | 2003-12-31 |
| PT1627639E (pt) | 2010-03-01 |
| ES2271269T3 (es) | 2007-04-16 |
| WO2002102297A3 (en) | 2003-05-01 |
| ATE338557T1 (de) | 2006-09-15 |
| EP1627639A3 (en) | 2006-09-27 |
| SI1627639T1 (sl) | 2010-04-30 |
| US20040204469A1 (en) | 2004-10-14 |
| EA009780B1 (ru) | 2008-04-28 |
| JP2008297308A (ja) | 2008-12-11 |
| EP1397145A2 (en) | 2004-03-17 |
| DE60234873D1 (de) | 2010-02-04 |
| AP1512A (en) | 2005-12-15 |
| JP4824727B2 (ja) | 2011-11-30 |
| ES2336682T3 (es) | 2010-04-15 |
| WO2002102297A2 (en) | 2002-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109949T1 (el) | Χρηση αναστολεων cox-2 για τη θεραπεια σχιζοφρενειας, διαταραχων παραισθησεων | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| CY1124931T1 (el) | Αντιμετωπιση της φαινυλκετονουριας με bh4 | |
| CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
| ECSP077223A (es) | Indazoles utiles en el tratamiento de enfermedades cardiovasculares | |
| CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
| CY1115350T1 (el) | Χρησεις αναστολεων της dpp iv | |
| CY1118061T1 (el) | Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση | |
| CR8410A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares | |
| ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
| CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
| GT201000082A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
| DE502007002289D1 (de) | Methacrylatharze zur herstellung von fahrbahnmarkierungen | |
| CY1113160T1 (el) | Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων | |
| GT200300289A (es) | Derivados de pirrolopirimidina | |
| CY1117217T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης | |
| CY1115416T1 (el) | Συνθεση που περιεχει στατινες και ωμεγα-3 λιπαρα οξεα | |
| CY1114272T1 (el) | Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων | |
| HRP20130797T1 (en) | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase | |
| ATE346070T1 (de) | Purinderivate als kinaseinhibitoren | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| CY1110854T1 (el) | Πυραζολοπυριμιδινες θειαζολιου ως ανταγωνιστες υποδοχεων crf1 | |
| CY1113435T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο | |
| CY1114735T1 (el) | Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5 | |
| ECSP066802A (es) | Nuevas amidas de ácidos carboxílicos como inhibidores del factor xa |